Intersect ENT Initial Public Offering

Palo Alto, Calif. – Cooley advised Intersect ENT on its $63.3 million IPO. Intersect is a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. The company now trades on the Nasdaq Global Stock Market under the symbol "XENT."

Thus far in 2014, Cooley has advised on 70 completed public offerings, including 35 completed IPOs.

Related Contacts
Matthew Hemington Partner, Palo Alto
Brett White Of Counsel, Palo Alto
Seth Gottlieb Partner, Palo Alto
Matt Fleming Associate, Palo Alto
Mark Windfeld-Hansen Partner, Palo Alto
Renee Deming Retired Partner, Palo Alto
Natasha Leskovsek Partner, Washington, DC
Phil Mitchell Partner, New York